Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours

Background: Peptide receptor radionuclide therapy (PRRT) is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours (GEP NETs), Although Phase III randomised clinical trial data is not available for NETs of other site of origin, in practice, PRRT is used more widely in clini...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Lim, Lisi Elizabeth, Chan, David L., Thomas, David, Du, Yang, Tincknell, Gary, Kuchel, Anna, Davis, Alexander, Bailey, Dale L., Pavlakis, Nick, Cehic, Gabrielle, Macdonald, William, Wyld, David, Segelov, Eva
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2020
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7343632/
https://ncbi.nlm.nih.gov/pubmed/32676165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27659
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items